Market Overview

Array BioPharma And Others Shine At The ESMO 2017 Congress

Array BioPharma And Others Shine At The ESMO 2017 Congress
Related LLY
Long Wait Is Over: Election Day Dawns With Markets Under Light Pressure
A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings
FDA rejects Aquestive's marketing application for tadalafil oral film (Seeking Alpha)
Related ARRY
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs
The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

The 2017 ESMO Congress wraps up on Tuesday in Madrid, Spain. On Monday, Jefferies issued a handful of flash notes related to companies presenting at the conference.

Here’s a breakdown of the highlights.

Five Prime Therapeutics

Five Prime Therapeutics Inc (NASDAQ: FPRX) reported positive data on its Phase I trials of FP-1039 in treatment of mesothelioma.

“Currently we do not include FP-1039 in our valuation; thus, if successfully developed, it would provide upside,” analyst Eun Yang wrote.

Bristol-Myers Squibb

Analyst Jeffrey Holford said new data on Bristol-Myers Squibb Co (NYSE: BMY)’s CM-214 suggests the market is prematurely writing off Yervoy.

“We see the CM-214 data driving a new indication and growth for Yervoy, helping to support our above consensus 2021E revenue estimate of $3.1bn vs. consensus of $1.8bn,” Holford wrote.

Eli Lilly

Holford said early indications suggest Eli Lilly and Co (NYSE: LLY) breast cancer treatment drug Abema could be the best in its class in terms of efficacy, but more data will be needed to support the initial findings.

“We see room for upside against our own and consensus estimates for Abema and have previously estimated that this could increase mid-term EPS and valuation for LLY by c3%-5%,” he wrote.

Related Link: What Pharmaceuticals Spend On Lobbying To Influence Trump

Array Biopharma

Array Biopharma Inc (NASDAQ: ARRY) reported some positive safety data from its ongoing Phase III BEACON trial. Yang said the new data suggests major potential for Array’s melanoma combination treatment.

“Aside from potential bini/enco approval by ~mid-2018 in somewhat crowded melanoma market, its combo potential in unmet CRC indication with limited competition & ~$1B market size represents likely upside, if successful,” Yang wrote.

Price Targets And Ratings

Jefferies maintains the following ratings and price targets on the four stocks mentioned above:

  • Five Prime—Buy rating, $52 price target
  • Bristol Myers—Buy rating, $66 price target
  • Eli Lilly—Buy rating, $89 price target
  • Array Biopharma—Buy rating, $9 price target

Latest Ratings for LLY

Oct 2018Credit SuisseUpgradesUnderperformNeutral
Oct 2018Wolfe ResearchInitiates Coverage OnPeer Perform
Oct 2018BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: ESMOAnalyst Color Biotech News Price Target Events Analyst Ratings General Best of Benzinga


Related Articles (ARRY + BMY)

View Comments and Join the Discussion!

Latest Ratings

BKNGWells FargoUpgrades0.0
DARJP MorganUpgrades25.0
HPCredit SuisseUpgrades65.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

FireEye Higher After Equifax Security Breach, Analyst Upgrade

Munster: iPhone 8 Should Be Delivered On Time